Dear SSRP colleagues,
I have four, 60+ y.o, male patients who were doing very well on testosterone cypionate IM therapy. Their total T levels were in the 600 range. CJC-1295+Ipamorelin 0.1 ml (100 mcg) SQ QHS 5 days/week (M-F) was added for anti-aging.
Lab testing performed about 3 months after initiation of the CJC-1295+Ipamorelin revealed significant insulin resistance, i.e., HOMA-IR ovder 4.0, which did not exist prior to the CJC-1295+Ipamorelin therapy. Their pre-treatment HOMA-IR values were in the 0.7 to 1.2 range, which is WNL. They all have healthy diets, good quality supplementation, and regular exercise regimens.
I am requesting input on the best clinical course of action:
- Decrease dosage of CJC-1295+Ipamorelin to 0.05 ml (50 mcg) SQ QHS 5 days/week (M-F)?
- Discontinue 0.1 ml (100 mcg) SQ QHS 5 days/week (M-F)?
- Add GLP1-RA therapy, i.e. Exenatide 0.05-0.10 ml (5-10 units) QAM?
- Add GLP1-RA therapy, i.e. Exenatide 0.05-0.10 ml (5-10 units) BID?
Thank you for sharing your insights.
Mitch Fleisher, M.D., D.Ht., D.A.B.F.M.